366 related articles for article (PubMed ID: 27803079)
1. Effect of Botulinum Toxin and Surgery among Spasmodic Dysphonia Patients.
van Esch BF; Wegner I; Stegeman I; Grolman W
Otolaryngol Head Neck Surg; 2017 Feb; 156(2):238-254. PubMed ID: 27803079
[TBL] [Abstract][Full Text] [Related]
2. Surgery or botulinum toxin for adductor spasmodic dysphonia: a comparative study.
Mendelsohn AH; Berke GS
Ann Otol Rhinol Laryngol; 2012 Apr; 121(4):231-8. PubMed ID: 22606926
[TBL] [Abstract][Full Text] [Related]
3. Adductor spasmodic dysphonia: Botulinum toxin a injections or laser thyroarytenoid myoneurectomy? A comparison from the patient perspective.
Schuering JHC; Heijnen BJ; Sjögren EV; Langeveld APM
Laryngoscope; 2020 Mar; 130(3):741-746. PubMed ID: 31169922
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin treatment of false vocal folds in adductor spasmodic dysphonia: Functional outcomes.
Simpson CB; Lee CT; Hatcher JL; Michalek J
Laryngoscope; 2016 Jan; 126(1):118-21. PubMed ID: 26467807
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Onabotulinum Toxin A Treatment for Adductor Spasmodic Dysphonia and Laryngeal Tremor.
Patel PN; Kabagambe EK; Starkweather JC; Keller M; Gamsarian V; Lee J; Kulkarni V; Garrett CG; Francis DO
JAMA Otolaryngol Head Neck Surg; 2018 Apr; 144(4):293-299. PubMed ID: 29423509
[TBL] [Abstract][Full Text] [Related]
6. A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia.
Morzaria S; Damrose EJ
J Voice; 2012 May; 26(3):378-80. PubMed ID: 20951552
[TBL] [Abstract][Full Text] [Related]
7. Interarytenoid muscle botox injection for treatment of adductor spasmodic dysphonia with vocal tremor.
Kendall KA; Leonard RJ
J Voice; 2011 Jan; 25(1):114-9. PubMed ID: 20137891
[TBL] [Abstract][Full Text] [Related]
8. Differences in botulinum toxin dosing between patients with adductor spasmodic dysphonia and essential voice tremor.
Orbelo DM; Duffy JR; Hughes Borst BJ; Ekbom D; Maragos NE
J Voice; 2014 Jan; 28(1):123-7. PubMed ID: 24080335
[TBL] [Abstract][Full Text] [Related]
9. Relationship of laryngeal botulinum toxin dosage to patient age, vitality, and socioeconomic issues.
Young DL; Halstead LA
J Voice; 2014 Sep; 28(5):614-7. PubMed ID: 24954039
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin treatment of adductor spasmodic dysphonia: longitudinal functional outcomes.
Novakovic D; Waters HH; D'Elia JB; Blitzer A
Laryngoscope; 2011 Mar; 121(3):606-12. PubMed ID: 21298641
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of voice quality in adductor spasmodic dysphonia before and after botulinum toxin treatment.
Langeveld TP; van Rossum M; Houtman EH; Zwinderman AH; Briaire JJ; Baatenburg de Jong RJ
Ann Otol Rhinol Laryngol; 2001 Jul; 110(7 Pt 1):627-34. PubMed ID: 11465821
[TBL] [Abstract][Full Text] [Related]
12. Endoscopic laser thyroarytenoid myoneurectomy in patients with adductor spasmodic dysphonia: a pilot study on long-term outcome on voice quality.
Tsuji DH; Takahashi MT; Imamura R; Hachiya A; Sennes LU
J Voice; 2012 Sep; 26(5):666.e7-12. PubMed ID: 21940146
[TBL] [Abstract][Full Text] [Related]
13. Unilateral versus bilateral botulinum toxin injections in adductor spasmodic dysphonia in a large cohort.
Dharia I; Bielamowicz S
Laryngoscope; 2020 Nov; 130(11):2659-2662. PubMed ID: 31837152
[TBL] [Abstract][Full Text] [Related]
14. Spasmodic dysphonia: a seven-year audit of dose titration and demographics in the Indian population.
Nerurkar NK; Banu TP
J Laryngol Otol; 2014 Jul; 128(7):649-53. PubMed ID: 24999662
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Botulinum Toxin Injections and Type 2 Thyroplasty for Adductor Spasmodic Dysphonia.
Sanuki T; Takemoto N
Laryngoscope; 2023 Dec; 133(12):3443-3448. PubMed ID: 37278482
[TBL] [Abstract][Full Text] [Related]
16. Factors influencing botulinum toxin dose instability in spasmodic dysphonia patients.
Rosow DE; Pechman A; Saint-Victor S; Lo K; Lundy DS; Casiano RR
J Voice; 2015 May; 29(3):352-5. PubMed ID: 25242042
[TBL] [Abstract][Full Text] [Related]
17. Quantitative laryngeal electromyography parameters may correlate with improved outcomes following botulinum toxin injection for spasmodic dysphonia.
Dwyer CD; Leclerc AA; Nandedkar SD; Young VN; Rosen CA
Muscle Nerve; 2021 Apr; 63(4):525-530. PubMed ID: 33382480
[TBL] [Abstract][Full Text] [Related]
18. Current practices in the management of adductor spasmodic dysphonia.
Eskander A; Fung K; McBride S; Hogikyan N
J Otolaryngol Head Neck Surg; 2010 Oct; 39(5):622-30. PubMed ID: 20828529
[TBL] [Abstract][Full Text] [Related]
19. Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia.
Rosow DE; Parikh P; Vivero RJ; Casiano RR; Lundy DS
Otolaryngol Head Neck Surg; 2013 Jun; 148(6):1003-6. PubMed ID: 23535709
[TBL] [Abstract][Full Text] [Related]
20. Retrospective review of dosing trends in botulinum toxin injections for the treatment of adductor spasmodic dysphonia in a long-term cohort.
French G; Bosch JD; Randall DR
J Otolaryngol Head Neck Surg; 2020 Jan; 49(1):4. PubMed ID: 31937363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
